Comparing the Survival of Testicular Cancer across Healthcare Systems
Research type
Research Study
Full title
Comparing the Survival of Testis Cancer across Healthcare Systems: A Population -based Assessment
IRAS ID
193686
Contact name
Prokar Dasgupta
Contact email
Duration of Study in the UK
0 years, 4 months, 13 days
Research summary
Although testicular cancer can potentially arise in all age groups, it is most commonly found in young adult men. While it constitutes the largest share of cancers in this population, survival rates are generally excellent, reaching nearly 100% for early stage/grade. To achieve cure, different treatments are employed; normally the affected testicle is surgically removed; if the tumour has spread to other parts of the body, chemotherapy and/or radiotherapy are also given. Presumably, treatment patterns for testicular cancer differ among countries and their respective health systems. For example, radiation therapy has been the mainstay in North America for certain tumour stages, while in Europe, chemotherapy was favoured for these tumours. The effect of health systems on the utilization of different treatment strategies is unknown. More importantly, the use of these treatments among low-income strata remain undetermined. We aim to address this gap in knowledge using population-based data from different countries.
REC name
East of Scotland Research Ethics Service REC 1
REC reference
16/ES/0033
Date of REC Opinion
26 Feb 2016
REC opinion
Favourable Opinion